Abstract
Mycoplasma genitalium is a sexually transmitted pathogen, which can cause a range of reproductive tract diseases in both men and women. To disentangle the relationship between M. genitalium infection(s) and subsequent reproductive health complications at the population level, accurate serological tools are needed. The major challenge in developing specific M. genitalium serological tests is the extensive cross-reactivity with the closely related ubiquitous respiratory tract pathogen, M. pneumoniae. In this report, we describe the development of an immunoblot assay based on a recombinant fragment of the M. genitalium MG075 protein present in lipid-associated membrane extracts. A sensitivity of 87.1% was achieved based on testing antibody responses in sera from 101 adults with PCR-confirmed M. genitalium infection. A specificity of 95.2% was obtained through evaluation of sera from 166 children under 15 years of age with and without M. pneumoniae infection, who were unlikely to have been exposed to sexually transmitted M. genitalium. The development of a serological assay capable of accurately distinguishing M. genitalium and M. pneumoniae, will enable a better understanding of associations between M. genitalium and adverse reproductive sequelae.
Competing Interest Statement
JSJ reports grants, personal fees, and non-financial support from Hologic; grants and personal fees from Nabriva, and personal fees from LeoPharma, Abbott, and BioMerieux all outside the submitted work.
Funding Statement
Parts of the present work were funded by an NIH grant to Brandie Taylor (1R01AI143653-01A1) with JSJ as sub-PI, an NIH/NIAID grant to Lisa Manhart (R01 AI61019) with JSJ as subcontractor. Furthermore, this work was supported in part by the grant: Gulf South Sexually Transmitted Infections/Topical Microbicide Cooperative Research Center (NIAID grant no. U19 AI061972) and the Intramural Research Program of the NIH Clinical Center, Bethesda, Maryland, USA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Mg positive samples were from Louisiana State University, United States of America, where written informed consent was obtained from participants and the study protocol was approved by the Institutional Review Board of the Louisiana State University Health Sciences Center. All Mg positive samples used in the study were fully anonymised (also to research group) and originally collected with consent for further serological work. Sample set 1 Uppsala Research Ethical Committee (journal no. 2010/429) and Sample set 2: Karolinska University Hospital Ethics Committee in Stockholm, Sweden, D.nr: 392/01. The use of fully anonymised Mg negative samples was not subject to ethical review and approval, as this was not required according to the Danish Legislation and Institutional Requirements (Statens Serum Institut). Furthermore, written informed consent was not required for this study in accordance with the National Legislation and the Institutional Requirements.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
